论文部分内容阅读
目的分析结直肠癌患者肿瘤组织中KRAS、NRAS及BRAF基因突变情况。方法选取2013年2月—2016年5月来本院就诊的结直肠癌患者210例,收集肿瘤组织,采用PCR+直接测序技术分别监测KRAS和NRAS基因的ex-2、ex-3、ex-4外显因子及BRAF基因ex-15外显因子的突变情况。结果 KRAS、NRAS、BRAF基因突变率分别为43.8%、1.9%、5.2%。其中KRAS基因突变主要以ex-2外显因子的codon 12和codon 13密码子为主,分别占总突变的64.1%、13.0%;ex-3外显因子的突变主要以codon59和codon61位密码子为主;ex-4外显因子的突变主要以codon117和codon146位密码子为主。结论结直肠患者肿瘤组织中KRAS基因ex-2外显因子突变发生率最高,增加KRAS基因检测位点的同时联合检测NRAS、BRAF基因,能准确定位靶向治疗的最佳受益者。
Objective To analyze the mutations of KRAS, NRAS and BRAF in tumor tissues of patients with colorectal cancer. Methods Totally 210 colorectal cancer patients from our hospital from February 2013 to May 2016 were enrolled in this study. Tumor tissues were collected and the exosomes ex-2, ex-3 and ex-4 of KRAS and NRAS were detected by PCR + direct sequencing Explicit factors and BRAF gene ex-15 mutations in the external factors. Results The mutation rates of KRAS, NRAS and BRAF genes were 43.8%, 1.9% and 5.2% respectively. Among them, KRAS gene mutation mainly consisted of codon 12 and codon 13 codons of ex-2 exponent, accounting for 64.1% and 13.0% of the total mutations, respectively. Mutations of ex-3 exponent were mainly codon59 and codon61 codons The main exon-4 mutations were codon117 and codon146 codon. Conclusions The incidence of KRAS exon 2 mutations in colorectal cancer patients is the highest, and the detection of KRAS gene plus the detection of NRAS and BRAF genes in colorectal cancer patients can accurately locate the targeted beneficiaries of targeted therapy.